Safety and Efficacy of Ceritinib for Patients With ALK+ NSCLC Metastatic to the Brain and/or Leptomeninges
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Clin. Cancer Res 2022 Jan 28;[EPub Ahead of Print], LQM Chow, F Barlesi, EM Bertino, et alFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.